KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBT Margin (2016 - 2025)

Historic EBT Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 20.02%.

  • Pfizer's EBT Margin fell 66200.0% to 20.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.82%, marking a year-over-year increase of 229100.0%. This contributed to the annual value of 12.61% for FY2024, which is 108300.0% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's EBT Margin is 20.02%, which was down 66200.0% from 20.77% recorded in Q2 2025.
  • In the past 5 years, Pfizer's EBT Margin registered a high of 172.87% during Q2 2023, and its lowest value of 120.24% during Q4 2023.
  • Moreover, its 5-year median value for EBT Margin was 29.63% (2021), whereas its average is 26.73%.
  • As far as peak fluctuations go, Pfizer's EBT Margin surged by 1376000bps in 2023, and later crashed by -1498800bps in 2024.
  • Over the past 5 years, Pfizer's EBT Margin (Quarter) stood at 32.63% in 2021, then grew by 22bps to 39.76% in 2022, then crashed by -402bps to 120.24% in 2023, then soared by 122bps to 26.64% in 2024, then dropped by -25bps to 20.02% in 2025.
  • Its EBT Margin stands at 20.02% for Q3 2025, versus 20.77% for Q2 2025 and 20.31% for Q1 2025.